Pasithea Therapeutics Corp.
KTTA
$0.77
-$0.03-4.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.54% | 0.21% | -13.47% | -16.69% | -10.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.14% | -14.12% | -18.73% | -17.37% | -10.82% |
| Operating Income | -17.14% | 14.12% | 18.73% | 17.37% | 10.82% |
| Income Before Tax | -46.91% | 14.36% | 17.80% | 15.50% | 10.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.91% | 14.36% | 17.80% | 15.50% | 10.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.91% | 14.46% | 17.88% | 16.44% | 12.89% |
| EBIT | -17.14% | 14.12% | 18.73% | 17.37% | 10.82% |
| EBITDA | -17.86% | 14.83% | 19.47% | 18.06% | 11.28% |
| EPS Basic | 72.92% | 64.86% | 48.23% | 23.42% | 1.52% |
| Normalized Basic EPS | 75.47% | 64.79% | 48.12% | 22.55% | -1.33% |
| EPS Diluted | 72.92% | 64.86% | 48.23% | 23.42% | 1.52% |
| Normalized Diluted EPS | 75.47% | 64.79% | 48.12% | 22.55% | -1.33% |
| Average Basic Shares Outstanding | 540.17% | 279.90% | 122.10% | 14.88% | -13.95% |
| Average Diluted Shares Outstanding | 540.17% | 279.90% | 122.10% | 14.88% | -13.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |